ILA Stock Overview
A drug research and repurposing company, focuses on the development of preventative or therapeutic drugs for viral infections in Australia and the United States of America. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Island Pharmaceuticals Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.17 |
| 52 Week High | AU$0.20 |
| 52 Week Low | AU$0.05 |
| Beta | 0.052 |
| 11 Month Change | 37.50% |
| 3 Month Change | 150.00% |
| 1 Year Change | 106.25% |
| 33 Year Change | -42.11% |
| 5 Year Change | n/a |
| Change since IPO | -68.57% |
Recent News & Updates
Recent updates
Shareholder Returns
| ILA | AU Pharmaceuticals | AU Market | |
|---|---|---|---|
| 7D | -8.3% | -16.4% | 0.9% |
| 1Y | 106.3% | 32.3% | 18.4% |
Return vs Industry: ILA exceeded the Australian Pharmaceuticals industry which returned 32.2% over the past year.
Return vs Market: ILA exceeded the Australian Market which returned 18.4% over the past year.
Price Volatility
| ILA volatility | |
|---|---|
| ILA Average Weekly Movement | 21.9% |
| Pharmaceuticals Industry Average Movement | 11.9% |
| Market Average Movement | 8.5% |
| 10% most volatile stocks in AU Market | 17.5% |
| 10% least volatile stocks in AU Market | 3.2% |
Stable Share Price: ILA's share price has been volatile over the past 3 months compared to the Australian market.
Volatility Over Time: ILA's weekly volatility has increased from 16% to 22% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | n/a | David Foster | www.islandpharmaceuticals.com |
Island Pharmaceuticals Limited, a drug research and repurposing company, focuses on the development of preventative or therapeutic drugs for viral infections in Australia and the United States of America. Its lead product candidate is ISLA-101, a drug for the prevention and treatment of dengue fever and other mosquito borne diseases. The company has a collaboration agreement with Monash University and National Cancer Institute IND.
Island Pharmaceuticals Limited Fundamentals Summary
| ILA fundamental statistics | |
|---|---|
| Market cap | AU$25.73m |
| Earnings (TTM) | -AU$2.86m |
| Revenue (TTM) | AU$1.25m |
20.6x
P/S Ratio-9.0x
P/E RatioIs ILA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ILA income statement (TTM) | |
|---|---|
| Revenue | AU$1.25m |
| Cost of Revenue | AU$2.27m |
| Gross Profit | -AU$1.02m |
| Other Expenses | AU$1.84m |
| Earnings | -AU$2.86m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.018 |
| Gross Margin | -81.58% |
| Net Profit Margin | -228.86% |
| Debt/Equity Ratio | 27.8% |
How did ILA perform over the long term?
See historical performance and comparison